Day One Biopharmaceuticals Inc.

09/08/2025 | Press release | Archived content

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Day One Biopharmaceuticals Inc. published this content on September 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 23, 2026 at 14:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]